EpiNews - US FDA advisers discuss Pfizer's maternal RSV vaccine

US FDA advisers discuss Pfizer's maternal RSV vaccine

May 18, 2023

Maternal and Child Health

US FDA advisers discuss Pfizer's maternal RSV vaccine

May 18 (Reuters) - Advisers to the U.S. Food and Drug Administration on Thursday began discussing Pfizer Inc's (PFE.N) experimental respiratory syncytial virus (RSV) vaccine intended to protect infants through six months of age when given to expectant mothers.

Tags:

Pfizer FDA infants RSV vaccine

FDA authorizes first at-home test that can detect both flu and Covid-19

FDA authorizes first at-home test that can detect both flu and Covid-19

FDA asks drugmakers to update Covid boosters to target XBB.1.5 for the fall

FDA asks drugmakers to update Covid boosters to target XBB.1.5 for the fall